Axonics (Nasdaq:AXNX) - 주가, 뉴스 및 분석

AXNX 주식 개요

는 방광 및 장 기능 장애 치료를 위한 새로운 제품을 개발 및 상용화하는 의료 기술 회사입니다. 자세한 내용

AXNX 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	4/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 67.3% 에서 거래

수익은 매년 55.07% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 28.1% 증가했습니다.

위험 분석

위험 검사에서 AXNX 에 대한 위험이 감지되지 않았습니다.

Axonics, Inc. 경쟁사

Inari Medical

NasdaqGS:NARI

US$3.0b

Inspire Medical Systems

NYSE:INSP

US$5.2b

iRhythm Technologies

NasdaqGS:IRTC

US$2.5b

Integer Holdings

NYSE:ITGR

US$4.5b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Axonics
과거 주가
현재 주가	US$70.98
52주 최고치	US$71.05
52주 최저치	US$55.09
베타	0.83
11개월 변경	1.00%
3개월 변경 사항	3.12%
1년 변경 사항	24.48%
33년 변화	18.12%
5년 변화	220.89%
IPO 이후 변화	373.83%

최근 뉴스 및 업데이트

Axonics' Market Growth Strengthens Boston Scientific's Future

Nov 05

Recent updates

Axonics' Market Growth Strengthens Boston Scientific's Future

Nov 05

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Jul 14

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Jun 20

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Mar 27

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Feb 28

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

May 30

Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

Apr 19

주주 수익률

	AXNX	US Medical Equipment	US 마켓
7D	0.8%	-1.1%	-2.1%
1Y	24.5%	22.8%	30.2%

수익률 대 산업: AXNX 지난 1년 동안 22.8 %를 반환한 US Medical Equipment 산업과 일치했습니다.

수익률 대 시장: AXNX 지난 1년 동안 30.2 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is AXNX's price volatile compared to industry and market?
AXNX volatility
AXNX Average Weekly Movement	0.5%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

안정적인 주가: AXNX 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: AXNX 의 주간 변동성( 1% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2012	797	Ray Cohen	www.axonics.com

는 의료 기술 회사로 방광 및 장 기능 장애 치료를 위한 새로운 제품의 개발 및 상용화에 종사하고 있습니다. 요절박성 요실금과 절박성 요실금, 변실금(FI), 비폐색성 요폐(UR)를 포함한 과민성 방광(OAB) 환자 치료에 사용되는 천골 신경조절(SNM) 시스템과 재충전식(R20) 및 재충전식(F15) 이식형 SNM 시스템은 목표 천골 신경에 약한 전기 펄스를 전달하여 뇌와의 정상적인 통신을 복원하여 OAB, UR 및 FI의 증상을 감소시키는 데 사용됩니다. 또한 여성 복압성 요실금 치료를 위한 요도 팽창제인 벌카미드도 제공합니다.

Axonics, Inc. 기본 사항 요약

Axonics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
AXNX 기본 통계
시가총액	US$3.60b
수익(TTM)	-US$5.66m
수익(TTM)	US$431.90m

8.4x

P/S 비율

-640.9x

P/E 비율

AXNX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
AXNX 손익 계산서(TTM)
수익	US$431.90m
수익 비용	US$101.10m
총 이익	US$330.81m
기타 비용	US$336.47m
수익	-US$5.66m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.11
총 마진	76.59%
순이익 마진	-1.31%
부채/자본 비율	0%

AXNX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

AXNX 주식 개요

보상

위험 분석

Axonics, Inc. 경쟁사

NasdaqGS:NARI

US$3.0b

NYSE:INSP

US$5.2b

NasdaqGS:IRTC

US$2.5b

NYSE:ITGR

US$4.5b

가격 내역 및 성능

최근 뉴스 및 업데이트

BBoston Scientific Corporation (NYSE:BSX) completed the acquisition of Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders.

Forecast breakeven date moved forward to 2024

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.08 in 3Q 2023)

Axonics' Market Growth Strengthens Boston Scientific's Future

Axonics, Inc. Prevails in Patent Infringement Lawsuit with Medtronic

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

BBoston Scientific Corporation (NYSE:BSX) completed the acquisition of Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders.

Forecast breakeven date moved forward to 2024

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.08 in 3Q 2023)

Axonics' Market Growth Strengthens Boston Scientific's Future

Axonics, Inc. Prevails in Patent Infringement Lawsuit with Medtronic

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

CEO & Director exercised options to buy US$7.1m worth of stock.

Forecast breakeven date moved forward to 2024

Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia

Forecast breakeven date pushed back to 2025

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

Medtronic Files Itc Action Against Axonics to Stop Unauthorized Use of Medtronic Innovations

Full year 2023 earnings: EPS exceeds analyst expectations

Chief Commercial Officer exercised options and sold US$1.1m worth of stock

Insufficient new directors

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion.

Chief Medical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Axonics, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Axonics, Inc. Announces Chief Financial Officer Changes

Chief Commercial Officer notifies of intention to sell stock

Forecast breakeven date moved forward to 2024

Axonics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Consensus estimates of losses per share improve by 37%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

President & CFO notifies of intention to sell stock

Now 20% undervalued after recent price drop

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Full year 2022 earnings: EPS exceeds analyst expectations

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Chief Operating Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

Executive VP exercised options and sold US$705k worth of stock

Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Chief Commercial Officer exercised options and sold US$1.9m worth of stock

Axonics, Inc. Provides Revenue Guidance for 2023

Forecast to breakeven in 2025

Axonics, Inc. to Report Fiscal Year 2022 Results on Jan 11, 2023

Independent Director recently sold US$135k worth of stock

Axonics, Inc. Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Year 2022

Axonics, Inc. to Report Q3, 2022 Results on Oct 31, 2022

Axonics stock falls 5.6% after Needham downgrades rating

Chief Technology Officer notifies of intention to sell stock

Executive VP exercised options and sold US$551k worth of stock

Chief Medical Officer recently sold US$748k worth of stock

Axonics Announces First Patient Implants in Canada with New Recharge-Free Sacral Neuromodulation System

Axonics Stock Is A Buy Amid Current Capex Cycle